APPH Stock Overview
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Apontis Pharma AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €8.24 |
| 52 Week High | €11.85 |
| 52 Week Low | €3.03 |
| Beta | 1.83 |
| 1 Month Change | 33.77% |
| 3 Month Change | 82.30% |
| 1 Year Change | -20.77% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -56.05% |
Recent News & Updates
Recent updates
Potential Upside For Apontis Pharma AG (ETR:APPH) Not Without Risk
Apr 05
We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth
Dec 02Not Many Are Piling Into Apontis Pharma AG (ETR:APPH) Stock Yet As It Plummets 27%
Jul 29Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors
Apr 08Shareholder Returns
| APPH | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 4.3% | -3.3% | -1.5% |
| 1Y | -20.8% | -30.8% | 0.9% |
Return vs Industry: APPH exceeded the German Pharmaceuticals industry which returned -31.3% over the past year.
Return vs Market: APPH underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| APPH volatility | |
|---|---|
| APPH Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: APPH's share price has been volatile over the past 3 months.
Volatility Over Time: APPH's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 177 | Bruno Wohlschlegel | apontis-pharma.de |
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company was founded in 1946 is headquartered in Monheim am Rhein, Germany.
Apontis Pharma AG Fundamentals Summary
| APPH fundamental statistics | |
|---|---|
| Market cap | €68.64m |
| Earnings (TTM) | -€11.30m |
| Revenue (TTM) | €36.96m |
1.9x
P/S Ratio-6.1x
P/E RatioIs APPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APPH income statement (TTM) | |
|---|---|
| Revenue | €36.96m |
| Cost of Revenue | €13.79m |
| Gross Profit | €23.17m |
| Other Expenses | €34.47m |
| Earnings | -€11.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -1.36 |
| Gross Margin | 62.68% |
| Net Profit Margin | -30.58% |
| Debt/Equity Ratio | 19.9% |
How did APPH perform over the long term?
See historical performance and comparison